CDMO Olon is continuing its expansion binge with a deal to buy an API plant in India that supplies ingredients to Novartis. The Italian generic drug and API maker said Tuesday that it is buying an API ...
Dublin, Sept. 18, 2025 (GLOBE NEWSWIRE) -- The "Active Pharmaceutical Ingredients Industry in India (2025 - 2030)" report has been added to ResearchAndMarkets.com's offering. In 2023, the active ...
ANKLESHWAR, India--(BUSINESS WIRE)--RUSAN PHARMA PRIVATE LIMITED, a pharmaceutical company based in India specializing in the area of addiction treatment and pain management, recently announced that ...
India is the largest provider of generic drugs globally. Indian pharmaceutical industry supplies over 50 per cent of global demand for various vaccines, 40 per cent of generic demand in the US and 25 ...
The global market for active pharmaceutical ingredients (APIs) in 2013 was estimated at US$ 119.7 billion and is projected to grow at a CAGR of 6.5% to a value of US$ 185.9 billion by 2020 The Asian ...
Ireland-based drugmaker Perrigo put its API plant in Ambernath, India, on the block earlier this year to reduce its growing debt, sources told RealMint. The facility, which has a capacity to ...
The Indian Active Pharmaceutical Ingredients (API) market in 2025 was valued at US$14.2 billion and is expected to grow at a CAGR of 8.5% to reach US$21.46 billion by 2030. In contrast, the global ...
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Indian API Market Outlook 2022" report to their offering. According to report on Indian API Market Outlook 2022, the ...
(MENAFN- GlobeNewsWire - Nasdaq) The Indian Active Pharmaceutical Ingredients (API) market, valued at INR 1.07 trillion in 2023, is set to reach INR 1.82 trillion by 2030, growing at a CAGR of ~8.26%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results